Key result
Compared with continuous-flow LVADs, pulsatile-flow LVADs significantly reduced the incidence of aortic insufficiency (10% vs 40%) and improved left ventricular ejection fraction (28% vs 19%) at 6 months.
Why the study?
Does a pulsatile flow LVAD improve left ventricular reverse remodeling and prevent aortic insufficiency compared to a continuous flow LVAD in patients with non-ischemic cardiomyopathy?
Cohort (n=40)
No
Does a pulsatile flow LVAD improve left ventricular reverse remodeling and prevent aortic insufficiency compared to a continuous flow LVAD in patients with non-ischemic cardiomyopathy?
Absolute Event Rate: 10% vs 40%
p-value: p=0.028
Pulsatile flow LVADs may offer advantages over continuous flow devices in promoting left ventricular reverse remodeling and preventing aortic insufficiency in patients with non-ischemic cardiomyopathy.
Pulsatile-flow LVADs may reduce aortic insufficiency and aid remodeling; hypothesis-generating and should not yet change practice without randomized confirmation.
BACKGROUND: A continuous flow (CF) left ventricular assist device (LVAD) has various advantages over a pulsatile flow (PF) LVAD, but the extent of preventing aortic insufficiency (AI) by each type of LVAD remains controversial. METHODS AND RESULTS: Of 86 patients with non-ischemic cardiomyopathy who underwent LVAD implantation between 2006 and 2015, 20 propensity score-matched patients with PF LVADs and 20 with CF LVADs were enrolled in this study. There were no significant differences in the baseline variables of both groups. During the 6-month LVAD treatment, the LV ejection fraction of the PF group was significantly higher than that of the CF group; the PF group also had a wider pulse pressure and less enlargement of the aortic root (P<0.05 for all). Patients in the PF group experienced more frequent opening of the native aortic valve and less AI than those in the CF group (P<0.05 for both). The PF LVAD was explanted in 5 patients (25%), and a CF LVAD was explanted in 1 patient (5%). CONCLUSIONS: Compared with CF LVADs, PF LVADs seem to have an advantage in improving LV reverse remodeling and preventing AI. It may be best to incorporate pulsatility into current CF LVADs while retaining their existing benefits.
No takes yet. Share an insight, caveat, or question.
Imamura et al. (2015) conducted a cohort in Non-ischemic cardiomyopathy requiring LVAD (n=40). Pulsatile-flow (PF) LVAD vs. Continuous-flow (CF) LVAD was evaluated on Aortic insufficiency at 6 months (p=0.028). Compared with continuous-flow LVADs, pulsatile-flow LVADs significantly reduced the incidence of aortic insufficiency (10% vs 40%) and improved left ventricular ejection fraction (28% vs 19%) at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: